Randomized controlled trial to evaluate the efficacy of Dheeradi Ghrita in the management of Attention Deficit Hyperactivity Disorder(ADHD) in children of age group 6 to 12 years

Anjali Pratap Thawrani1 个研究点分布在 1 个国家目标入组 60 人开始时间: 2025年9月7日最近更新: 2025年6月23日

试验速览

阶段: 2 期
状态: 尚未招募
发起方
入组人数: 60
试验地点: 1
主要终点: To study the effect of Dheeradi Ghrita in ADHD

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a randomized open labelled controlled clinical trial comparing the safety and efficacy of Dheeradi ghrita 4ml thrice a day with koshna jala and controlled shankhpushpi and jatamansi siddha ghrita 4ml thrice a day with koshna jala for 45 days in 60 children of age group 6 to 12 yrs with Attention Deficit Hyperactivity Disorder (ADHD)

研究设计

研究类型: Interventional
分配方式: Coin toss, Lottery, toss of dice, shuffling cards etc
盲法: Open Label

入排标准

年龄范围: 6.00 Year(s) 至 12.00 Year(s)（—）
性别: All

入选标准

•Age group between 6 to 12 yrs.
•Patient irrespective of their gender, religion and socioeconomic status.
•Patients having Symptoms of ADHD for at least last 6 months.
•Patients that fit in DSM IV criteria for diagnosis.
•Children with no other neurological condition like mental retardation, down syndrome, microcephaly, etc.

排除标准

•Any serious neurological disease diagnosed earlier like cerebral palsy, mental retardation, microcephaly.
•Any kind of systemic disease or chronic systemic disease like nephrotic syndrome, type 1 diabetes melitus.
•disobedient parents.

结局指标

主要结局

To study the effect of Dheeradi Ghrita in ADHD

时间窗: 15 days

次要结局

To understand the disease ADHD in detail.(To find out ayurvedic correlation of disease with doshas and dushya.)

研究者

发起方

Anjali Pratap Thawrani

申办方类型

Other [self]

研究点 (1)

Loading locations...

相似试验

已完成

3 期

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast CancerBreast Cancer Female

NCT02980965Fudan University249

终止

不适用

A Randomized Controlled Open Label Trial to Assess the Safety and Efficacy of the OptiVein IV Catheter in an Oncologic PopulationIntravenous Injections

NCT02420028Optomeditech Oy109

已完成

3 期

Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan ChildrenPlasmodium Falciparum

NCT03452475University of Oxford219

Unknown

不适用

Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19Covid19AKI

NCT04597034Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran35

进行中（未招募）

不适用

Coronary Artery Disease Reversal Treatment for patients suffering from Coronary Artery Disease.

CTRI/2018/09/015633Vaidya Sane Ayurvedic Lab Pvt Ltd30